

INFORMATION FOR APPLICANTS PREPARING A SUBMISSION FOR THE 2023 MEETING OF THE WHO EXPERT COMMITTEE ON SELECTION AND USE OF ESSENTIAL MEDICINES

Essential Medicines List Secretariat

DEPARTMENT OF HEALTH PRODUCTS POLICY AND STANDARDS



WHO/MHP/HPS/EML/2022.01

© World Health Organization 2022.

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization (<http://www.wipo.int/amc/en/mediation/rules/>).

Suggested citation. Information for applicants preparing a submission for the 2023 meeting of the WHO Expert Committee on Selection and Use of Essential Medicines. Geneva: World Health Organization; 2022 (WHO/MHP/HPS/EML/2022.01). Licence: [CC BY-NC-SA 3.0 IGO](#).

Cataloguing-in-Publication (CIP) data. CIP data are available at <http://apps.who.int/iris>.

Sales, rights and licensing. To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <https://www.who.int/copyright>.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

Preface

The 24th meeting of the WHO Expert Committee on the Selection and Use of Essential Medicines to revise and update the WHO Model List of Essential Medicines (EML) and Model List of Essential Medicines for Children (EMLc), will take place in April 2023.

This document describes the requirements for information to be included in submissions for inclusion of new medicines, for inclusion of new indications of currently listed medicines, and deletion of currently listed medicines for consideration by the Expert Committee.

For submissions relating to the inclusion or deletion of individual dosage form(s) and/or strength(s) of currently listed medicines for existing indications, please contact the EML Secretariat for further information.

During the submission period, the EML Secretariat is available to provide information and support to applicants, to ensure submissions adequately address the submission requirements. Final submissions must be emailed to the EML Secretariat (emlsecretariat@who.int) in both PDF and Word formats by **16 December 2022, 18:00 UTC**.

Please direct all enquiries to:

The Secretary
WHO Expert Committee on Selection and Use of Essential Medicines
Essential Medicines Team
Department of Health Products Policy and Standards
World Health Organization, Geneva
emlsecretariat@who.int

-
- All submissions accepted for consideration by the Expert Committee will be published on the WHO website and should not include information that is commercial in confidence.
-

Contents

1.	TITLE PAGE	1
2.	SUMMARY STATEMENT OF THE PROPOSAL FOR INCLUSION, CHANGE OR DELETION.....	2
3.	CONSULTATION WITH WHO TECHNICAL DEPARTMENTS	4
4.	OTHER ORGANIZATION(S) CONSULTED AND/OR SUPPORTING THE SUBMISSION	5
5.	KEY INFORMATION FOR THE PROPOSED MEDICINE(S)	6
	International non-proprietary name (INN) of the proposed medicine(s).....	6
	Anatomical therapeutic chemical (ATC) code of the proposed medicine(s)	6
	Dosage form(s) and strength(s) of the proposed medicine(s).....	6
	Indication(s)	6
6.	PROPOSAL FOR AN INDIVIDUAL MEDICINE OR REPRESENTATIVE OF A PHARMACOLOGICAL CLASS / THERAPEUTIC GROUP	7
7.	INFORMATION SUPPORTING THE PUBLIC HEALTH RELEVANCE	8
	NEW MEDICINE(S) / INDICATION(S)	8
	DELETIONS.....	8
8.	TREATMENT DETAILS	9
	Dosage regimen and duration of treatment	9
	Requirements to ensure appropriate use of the medicine(s)	9
	Recommendations in existing WHO guidelines.....	9
	Recommendations in other current clinical guidelines.....	9
9.	REVIEW OF BENEFITS: SUMMARY OF EVIDENCE OF COMPARATIVE EFFECTIVENESS	10
	NEW MEDICINE(S) / INDICATION(S)	10
	Systematic literature search.....	10
	Summary of available evidence for comparative effectiveness.....	11
	Assessment of applicability of the available evidence across diverse populations and settings	11
	DELETIONS.....	11
10.	REVIEW OF HARMS AND TOXICITY: SUMMARY OF EVIDENCE OF COMPARATIVE SAFETY	12
	NEW MEDICINE(S) / INDICATION(S)	12
	DELETIONS.....	12
11.	SUMMARY OF AVAILABLE DATA ON COMPARATIVE COST AND COST-EFFECTIVENESS	13
	NEW MEDICINE(S) / INDICATION(S)	13

DELETIONS.....	13
12. REGULATORY STATUS, MARKET AVAILABILITY AND PHARMACOPOIEAL STANDARDS.....	14
NEW MEDICINE(S) / INDICATION(S)	14
Regulatory status of the proposed medicine(s)	14
Market availability of the proposed medicine(s).....	14
Pharmacopoieal standards	14
DELETIONS.....	15
13. REFERENCES.....	16

Information to be included in submissions for inclusion or deletion of a medicine in the WHO Model Lists of Essential Medicines

1. TITLE PAGE

All submissions must have a title page describing the purpose of the submission and include the name and contact information of the individual(s) and/or organization(s) responsible.

2. SUMMARY STATEMENT OF THE PROPOSAL FOR INCLUSION, CHANGE OR DELETION

For **inclusions** of new medicines or new indications for currently listed medicines, briefly describe the proposal in terms of clinical indication(s), target population(s) and role in therapy for the requested medicine(s).

For **deletion** of medicines or indications, briefly describe the rationale and justification for the proposed deletion.

In all cases, specify whether the proposal relates to listing on the EML and/or EMLc, the core or complementary list, and of an individual medicine or as a representative of a pharmacological class or therapeutic group ("square box listing" – in which case the therapeutic alternatives should also be specified). For an explanation of the different terms, see below.

-
- The Essential Medicines List for Children (EMLc) is intended for use for children up to and including 12 years of age.
 - The core list presents a list of minimum medicine needs for a basic healthcare system, listing the most efficacious, safe and cost-effective medicines for priority conditions. Priority conditions are selected on the basis of current and estimated future public health relevance, and potential for safe and cost-effective treatment.
 - The complementary list presents essential medicines for priority diseases, for which specialized diagnostic or monitoring facilities, and/or specialist medical care, and/or specialist training are needed. In case of doubt, medicines may also be listed as complementary on the basis of consistent higher costs or less attractive cost-effectiveness in a variety of settings.
 - A "square box" symbol (□) is intended to indicate therapeutic alternatives to the listed medicine that may be considered for selection in national essential medicines lists. Alternatives may be individual medicines, or multiple medicines within a pharmacological class or chemical subgroup, defined at the 4th level of the [Anatomical Therapeutic Chemical \(ATC\) classification](#), which have similar clinical effectiveness and safety. The listed medicine should be the example of the class or subgroup for which there is the best evidence for effectiveness and safety. A square box is not used to indicate alternative generic brands of the same small molecule medicines, nor alternative biosimilars of biological medicines.
-

Summary statement examples (illustrative purpose only):

This submission advocates the inclusion of daratumumab as an individual medicine in the complementary list of the EML for the treatment of adult patients with newly diagnosed and relapsed or refractory multiple myeloma in transplant and non-transplant settings.

Results of the evidence syntheses indicate that adding daratumumab to standard combination regimens probably leads to clinically important gain of overall survival, yet a higher number of people experiencing adverse events or serious adverse events. Evidence further suggests that more people receiving daratumumab may have a clinically important gain of quality of life, than people no receiving daratumumab.

Multiple myeloma is the second most common haematological malignancy with a global incidence of approximately 140,000 and an age-standardized incidence rate of 2.1 per 100,000 population in 2016. Since 1990, the incidence rate increased by 126% worldwide.



This submission is made in support of the inclusion of calcipotriol on the core list of the EML and EMLc, for the treatment of plaque type psoriasis in adults and children. This proposal is being made because there are currently no topical alternatives to the use of topical corticosteroids for the treatment of psoriasis included on the Model Lists. Listing is proposed for calcipotriol as the representative of topical vitamin D analogues, with therapeutic alternatives limited to calcitriol and tacalcitol.

Psoriasis is increasingly recognized as a disabling skin disease and has a worldwide distribution. Effective treatment of patients with mild to moderate plaque type psoriasis with calcipotriol has been reported in different clinical environments and in different age groups. Inclusion of calcipotriol on the Model Lists for the proposed indication would widen access to appropriate medications for the treatment of psoriasis and provide an effective alternative for the many patients with mild to moderate forms of this chronic condition who comprise the majority of cases.



This submission proposes the deletion of coquinavir (solid oral dosage form, 200 mg) from the core list of

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_23337

